All Updates

All Updates

icon
Filter
Product updates
SOHM to launch ABBIE genome-editing technology in Q3 2024
Human Gene Editing
May 22, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Jun 20, 2024
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Jun 20, 2024
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Jun 20, 2024
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Jun 20, 2024
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Jun 20, 2024
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Jun 20, 2024
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Jun 20, 2024
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Jun 20, 2024
Human Gene Editing

Human Gene Editing

May 22, 2024

SOHM to launch ABBIE genome-editing technology in Q3 2024

Product updates

  • SOHM, a biopharmaceutical company focused on developing gene-editing technologies, has provided a progress update on its newly acquired gene editing technology, ABBIE (A Binding Based Integrase Enzyme), that precisely incorporates foreign DNA into cell genomes. The product will be commercially launched as off-the-shelf kits by Q3 2024.

  • ABBIE’s features include its ability to provide researchers with a way to implant specific designs of foreign DNA into the genomes of cells, thus considerably enhancing the safety and ease of genetic modifications. The system increases the efficiency of gene insertions which, in turn, reduces both costs and time dedicated to such endeavors.

  • California-based SOHM is a biopharmaceutical company that develops and commercializes gene-editing technologies for research, synthetic biology, and therapeutic purposes. Focusing on precision medicine, SOHM aims to offer efficient, targeted gene-editing solutions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.